Literature DB >> 1262458

Distribution, blood transport, and degradation of antidiuretic hormone in man.

G Baumann, J F Dingman.   

Abstract

The distribution, blood transport, and metabolic clearance of physiological concentrations of antidiuretic hormone were studied in 10 hydrated normal subjects with radioiodinated arginine vasopressin (125I-AVP). At 37 degrees C no binding of 125I-AVP to plasma proteins could be demonstrated, but some metabolites were associated with plasma proteins. 125I-AVP was rapidly distributed into a space approximating the extracellular fluid volume. Metabolic breakdown products became demonstrable within minutes after injection. The mean metabolic clearance rate of 125I-AVP was 4.1 ml/min/kg and the mean plasma half-life 24.1 min. Renal clearance had a mean value of 80 ml/min and accounted for 27% of the total metabolic clearance. It is concluded that in man antidiuretic hormone circulates as a free (non-protein bound) peptide, diffuses readily into the extracellular fluid space, and is metabolized within minutes. A plasma half-life of 24 min is consistent with the duration of antidiuresis after hormone administration or release.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1262458      PMCID: PMC436762          DOI: 10.1172/JCI108377

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  28 in total

1.  Fluorometric assay of proteins in the nanogram range.

Authors:  P Böhlen; S Stein; W Dairman; S Udenfriend
Journal:  Arch Biochem Biophys       Date:  1973-03       Impact factor: 4.013

2.  Comparative experiments on the urinary excretion of exogenous oxytocin and vasopressin.

Authors:  S E Jensen; P Frandsen; A T Nielsen
Journal:  Acta Endocrinol (Copenh)       Date:  1973-08

Review 3.  Polyacrylamide gel electrophoresis.

Authors:  A Chrambach; D Rodbard
Journal:  Science       Date:  1971-04-30       Impact factor: 47.728

4.  Mechanism of inactivation of vasopressin and oxytocin by the isolated perfused rat kidney.

Authors:  R Walter; R H Bowman
Journal:  Endocrinology       Date:  1973-01       Impact factor: 4.736

5.  Monoido-oxytocin: demonstration of its biological activity and specific binding to isolated fat cells.

Authors:  E E Thompson; P Freychet; J Roth
Journal:  Endocrinology       Date:  1972-11       Impact factor: 4.736

6.  Coated charcoal immunoassay of insulin.

Authors:  V Herbert; K S Lau; C W Gottlieb; S J Bleicher
Journal:  J Clin Endocrinol Metab       Date:  1965-10       Impact factor: 5.958

7.  Radioimmunoassay of arginine vasopressin in human plasma.

Authors:  C G Beardwell
Journal:  J Clin Endocrinol Metab       Date:  1971-08       Impact factor: 5.958

8.  Relative potency of arginine-8-vasopressin and lysine-8-vasopressin in humans.

Authors:  L Miller; L Fisch; C R Kleeman
Journal:  J Lab Clin Med       Date:  1967-02

9.  Increased plasma arginine vasopressin in clinical adrenocortical insufficeincy and its inhibition by glucosteroids.

Authors:  A B Ahmed; B C George; C Gonzalez-Auvert; J F Dingman
Journal:  J Clin Invest       Date:  1967-01       Impact factor: 14.808

10.  Development and clinical application of a new method for the radioimmunoassay of arginine vasopressin in human plasma.

Authors:  G L Robertson; E A Mahr; S Athar; T Sinha
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

View more
  32 in total

1.  Experimental cardiac arrest treatment with adrenaline, vasopressin, or placebo.

Authors:  Manoel Ângelo Gomes Palácio; Edison Ferreira de Paiva; Luciano Cesar Pontes de Azevedo; Ari Timerman
Journal:  Arq Bras Cardiol       Date:  2013-11-01       Impact factor: 2.000

2.  The handling of immunoreactive vasopressin by the isolated perfused rat kidney.

Authors:  R Rabkin; L Share; P A Payne; J Young; J Crofton
Journal:  J Clin Invest       Date:  1979-01       Impact factor: 14.808

3.  Copeptin is associated with kidney length, renal function, and prevalence of simple cysts in a population-based study.

Authors:  Belen Ponte; Menno Pruijm; Daniel Ackermann; Philippe Vuistiner; Idris Guessous; Georg Ehret; Heba Alwan; Sonia Youhanna; Fred Paccaud; Markus Mohaupt; Antoinette Péchère-Bertschi; Bruno Vogt; Michel Burnier; Pierre-Yves Martin; Olivier Devuyst; Murielle Bochud
Journal:  J Am Soc Nephrol       Date:  2014-09-30       Impact factor: 10.121

Review 4.  Copeptin as a biomarker for prediction of prognosis of acute ischemic stroke and transient ischemic attack: a meta-analysis.

Authors:  Qian Xu; Yunfan Tian; Hao Peng; Hongmei Li
Journal:  Hypertens Res       Date:  2016-12-01       Impact factor: 3.872

5.  Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease.

Authors:  Esther Meijer; Stephan J L Bakker; Eric J van der Jagt; Gerjan Navis; Paul E de Jong; Joachim Struck; Ron T Gansevoort
Journal:  Clin J Am Soc Nephrol       Date:  2010-10-07       Impact factor: 8.237

6.  Vasopressin: route of administration and effects on canine hepatic and superior mesenteric arterial blood flows.

Authors:  J C Kerr; R W Hobson; R F Seelig; K G Swan
Journal:  Ann Surg       Date:  1978-02       Impact factor: 12.969

Review 7.  Copeptin in the diagnosis of vasopressin-dependent disorders of fluid homeostasis.

Authors:  Mirjam Christ-Crain; Wiebke Fenske
Journal:  Nat Rev Endocrinol       Date:  2016-01-22       Impact factor: 43.330

8.  Plasma vasopressin levels are closely associated with fetal hypotension and neuronal injury after hypoxia-ischemia in near-term fetal sheep.

Authors:  Christopher A Lear; Michi Kasai; Paul P Drury; Joanne O Davidson; Etsuko Miyagi; Laura Bennet; Alistair J Gunn
Journal:  Pediatr Res       Date:  2020-03-17       Impact factor: 3.756

9.  Biological variation of arginine vasopressin.

Authors:  Kurt J Sollanek; Jeffery S Staab; Robert W Kenefick; Samuel N Cheuvront
Journal:  Eur J Appl Physiol       Date:  2020-01-22       Impact factor: 3.078

10.  Comparison of vasopressin and triglycyl-lysine vasopressin on splanchnic and systemic hemodynamics in dogs.

Authors:  A T Blei; R J Groszmann; R Gusberg; H O Conn
Journal:  Dig Dis Sci       Date:  1980-09       Impact factor: 3.199

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.